DexCom, Inc.

NASDAQ:DXCM

Medical - Devices

Healthcare
$82.52 +1.27%

+$0.90 today

Market cap
$30.78B
Beta
1.44
P/E (TTM)
29.9
EPS (TTM)
$2.42
52W Low $54.11High $89.98

Volume 4.25M

Average 5.43M

DXCM EBITDA Margin

EBITDA as a percentage of revenue.

DexCom, Inc.NASDAQ: DXCM

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 29.7%

EBITDA Margin was 29.7% in Q2 FY2026, up 3.0 pp from a year earlier. On a trailing-twelve-month basis it was 31.4%, up 7.2 pp year over year. Over 3 fiscal years it widened by 9.7 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 21 analysts of 30.5% for the fiscal year ending Dec 2026, up from 29.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
29.7%+1.2 pp QoQ
Last fiscal yearDec 2025
29.1%+5.7 pp YoY
LTMJun 2026
31.4%+7.2 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+3.0 pp-5.0 pp-8.0 pp
1 year+5.7 pp+1.3 pp-4.4 pp
3 years+9.7 pp+4.1 pp-5.6 pp
5 years+9.8 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
29.1%
Year-over-year change
+5.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How DXCM compares with its peers on the latest reported figures

  • DXCM's LTM Jun 2026 EBITDA Margin of 31.4% is the highest of the 7 companies compared; the peer median is -32.3%.
  • Its year-over-year change of +7.2 pp is the 3rd highest of 6, against a peer median of +6.7 pp.
  • Over three fiscal years its change of +9.7 pp compares with a peer median of +7.7 pp.
DXCM Competitors Peer median
EBITDA Margin for DXCM and competitors
Company Period LTM level YoY 3-year change
DXCMDexCom, Inc.LTM Jun 202631.4% +7.2 pp+9.7 pp
PODDInsulet CorporationLTM Jun 202621.5% +4.3 pp+10.5 pp
MMEDMiniMed Group, Inc. Common StockLTM Jul 20265.2% —+4.9 pp
TNDMTandem Diabetes Care, Inc.LTM Mar 2026-7.0% +6.7 pp-8.0 pp
BBNXBeta Bionics, Inc.LTM Mar 2026-57.6% +41.1 pp+35348.3 pp
DRIODarioHealth Corp.LTM Mar 2026-151.9% -4.9 pp+45.9 pp
SENSSenseonics Holdings, Inc.LTM Mar 2026-198.5% +73.8 pp-1165.0 pp
MMEDVMiniMed Group, Inc.—— ——
Peer median (excluding DXCM) -32.3%+6.7 pp+7.7 pp

Competitors are the stored peer set for DXCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.45B2.91B3.62B4.03B4.66B
Cost of Revenue768M1.03B1.33B1.59B1.86B
Gross Profit1.68B1.88B2.29B2.44B2.8B
Gross Margin68.6%64.7%63.2%60.5%60.1%
Research & Development604.2M484.2M505.8M552.4M599.1M
Selling, General & Admin810.5M1.01B1.19B1.29B1.29B
Operating Expenses1.41B1.49B1.69B1.84B1.89B
Depreciation & Amortization102M155.9M186M217.7M251.8M
EBITDA377.6M565.3M916.7M945.7M1.36B
EBITDA Margin15.4%19.4%25.3%23.4%29.1%
Operating Income265.8M391.2M597.7M600M911.8M
Operating Margin10.9%13.4%16.5%14.9%19.6%
Interest Income1.7M23.8M135M134.2M112.7M
Interest Expense18.8M18.6M20.3M19M18.3M
Other Income / Expenses(9M)(400K)112.7M109M176.6M
Income Before Tax256.8M390.8M710.4M709M1.09B
Pre-Tax Margin10.5%13.4%19.6%17.6%23.3%
Income Tax Expense39.9M49.6M168.9M132.8M252.1M
Net Income216.9M341.2M541.5M576.2M836.3M
Net Margin8.9%11.7%14.9%14.3%17.9%
EPS (Basic)0.560.881.441.462.14
EPS (Diluted)0.510.801.301.422.09
Weighted Avg Shares386.9M389.4M386M404.63M390.2M
Weighted Avg Shares (Diluted)428.8M427.5M425.5M412.7M405.5M

DexCom, Inc.

NASDAQ:DXCM

Intrinsic Alpha fair value

Locked

Current Price

$82.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.